NO126800B - - Google Patents
Download PDFInfo
- Publication number
- NO126800B NO126800B NO00067/70A NO6770A NO126800B NO 126800 B NO126800 B NO 126800B NO 00067/70 A NO00067/70 A NO 00067/70A NO 6770 A NO6770 A NO 6770A NO 126800 B NO126800 B NO 126800B
- Authority
- NO
- Norway
- Prior art keywords
- inosine
- complex
- dimethylaminoisopropanol
- acid
- learning
- Prior art date
Links
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 97
- 229930010555 Inosine Natural products 0.000 claims description 91
- 229960003786 inosine Drugs 0.000 claims description 91
- POIVWEXWFKSJHL-UHFFFAOYSA-N 2-(dimethylamino)propan-2-ol Chemical compound CN(C)C(C)(C)O POIVWEXWFKSJHL-UHFFFAOYSA-N 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 11
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical class CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 3
- 229960002887 deanol Drugs 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 241000700159 Rattus Species 0.000 description 17
- 150000001414 amino alcohols Chemical class 0.000 description 16
- 229920002477 rna polymer Polymers 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241001529453 unidentified herpesvirus Species 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- -1 amino alcohol compound Chemical class 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- NHJUPEHXTLQRLI-UHFFFAOYSA-N 2-(dimethylamino)propan-2-ol;hydrochloride Chemical compound Cl.CN(C)C(C)(C)O NHJUPEHXTLQRLI-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002211 ultraviolet spectrum Methods 0.000 description 3
- PYSGFFTXMUWEOT-UHFFFAOYSA-N 3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCCO PYSGFFTXMUWEOT-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 108010024160 informosome Proteins 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002729 polyribosome Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RPPCFYFWGVIQFS-UHFFFAOYSA-N 1-(dimethylamino)butan-1-ol Chemical compound CCCC(O)N(C)C RPPCFYFWGVIQFS-UHFFFAOYSA-N 0.000 description 1
- NCXUNZWLEYGQAH-UHFFFAOYSA-N 1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C NCXUNZWLEYGQAH-UHFFFAOYSA-N 0.000 description 1
- COKMLVOGWBEPNX-UHFFFAOYSA-N 1-(dipropylamino)ethanol Chemical compound CCCN(C(C)O)CCC COKMLVOGWBEPNX-UHFFFAOYSA-N 0.000 description 1
- SVZXPYMXOAPDNI-UHFFFAOYSA-N 1-[di(propan-2-yl)amino]ethanol Chemical compound CC(C)N(C(C)C)C(C)O SVZXPYMXOAPDNI-UHFFFAOYSA-N 0.000 description 1
- IWSZDQRGNFLMJS-UHFFFAOYSA-N 2-(dibutylamino)ethanol Chemical compound CCCCN(CCO)CCCC IWSZDQRGNFLMJS-UHFFFAOYSA-N 0.000 description 1
- ZYKZPCXHDHXBJP-UHFFFAOYSA-N 2-(diethylamino)propan-2-ol Chemical compound CCN(CC)C(C)(C)O ZYKZPCXHDHXBJP-UHFFFAOYSA-N 0.000 description 1
- HZLYGAQNCRJBDT-UHFFFAOYSA-N 2-(ethylamino)propan-2-ol Chemical compound CCNC(C)(C)O HZLYGAQNCRJBDT-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- IVJISJACKSSFGE-UHFFFAOYSA-N formaldehyde;1,3,5-triazine-2,4,6-triamine Chemical compound O=C.NC1=NC(N)=NC(N)=N1 IVJISJACKSSFGE-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000008223 ribosides Chemical class 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Fodder In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85386469A | 1969-08-28 | 1969-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO126800B true NO126800B (OSRAM) | 1973-03-26 |
Family
ID=25317098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO00067/70A NO126800B (OSRAM) | 1969-08-28 | 1970-01-08 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US3646007A (OSRAM) |
| JP (2) | JPS493999B1 (OSRAM) |
| AT (1) | AT299457B (OSRAM) |
| BE (1) | BE755361A (OSRAM) |
| BR (1) | BR6915483D0 (OSRAM) |
| CA (1) | CA920125A (OSRAM) |
| CH (1) | CH530998A (OSRAM) |
| CS (1) | CS183616B2 (OSRAM) |
| DE (2) | DE1965431C3 (OSRAM) |
| DK (1) | DK137801B (OSRAM) |
| ES (1) | ES375387A1 (OSRAM) |
| FR (1) | FR2068522B1 (OSRAM) |
| GB (1) | GB1252401A (OSRAM) |
| HU (1) | HU162297B (OSRAM) |
| IL (1) | IL35135A (OSRAM) |
| LU (1) | LU61603A1 (OSRAM) |
| NL (1) | NL140735B (OSRAM) |
| NO (1) | NO126800B (OSRAM) |
| PH (2) | PH9221A (OSRAM) |
| PL (1) | PL80960B1 (OSRAM) |
| SE (1) | SE384866B (OSRAM) |
| SU (1) | SU381216A3 (OSRAM) |
| YU (1) | YU36188B (OSRAM) |
| ZA (1) | ZA705913B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2260331B1 (OSRAM) * | 1974-02-08 | 1978-01-13 | Mauvernay Centre Europ Rech | |
| US4221909A (en) * | 1978-09-15 | 1980-09-09 | Sloan-Kettering Institute For Cancer Research | P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines |
| US4387226A (en) * | 1981-08-26 | 1983-06-07 | Newport Pharmaceuticals International, Inc. | Purine-dihydrothiazoles |
| US4510144A (en) * | 1981-08-26 | 1985-04-09 | Newport Pharmaceuticals International | Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives |
| JPS5994567U (ja) * | 1982-12-15 | 1984-06-27 | 松下電工株式会社 | 折り畳みドアのラツチ構造 |
| US4512981A (en) * | 1982-12-20 | 1985-04-23 | Newport Pharmaceuticals International, Inc. | Method of treating inflammation using inosiplex |
| DE3404315C1 (de) * | 1984-02-08 | 1985-05-09 | Newport AG, Zug | Verwendung von Inosin-haltigen Wirkstoffen zur Wachstumsfoerderung bei der Mast von Nutztieren |
| FR2652003A1 (fr) * | 1989-09-20 | 1991-03-22 | Delalande Sa | Utilisation d'un complexe de l'inosine avec un n,n-dialkylamino alcanol ou un sel de celui-ci avec un acide pharmacologiquement acceptable pour le traitement de certaines infections helminthiques. |
| US7585850B2 (en) * | 2004-02-10 | 2009-09-08 | Adenobio N.V. | Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases |
| JP2015536940A (ja) | 2012-10-29 | 2015-12-24 | シプラ・リミテッド | 抗ウイルス性ホスホネート類似体及びその製造方法 |
| CN104744541A (zh) * | 2014-05-05 | 2015-07-01 | 深圳信立泰药业股份有限公司 | 一种异丙肌苷新晶型、其制备方法及含有该新晶型的药物组合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB879259A (en) * | 1956-11-20 | 1961-10-11 | Riker Laboratories Inc | Acid addition salts of 2-dimethylaminoethanol and central nervous system stimulant compositions containing them |
| US3438968A (en) * | 1966-06-23 | 1969-04-15 | Int Chem & Nuclear Corp | Substituted ammonium basic addition salts of ribonucleic acid |
-
0
- BE BE755361D patent/BE755361A/xx not_active IP Right Cessation
-
1969
- 1969-08-28 US US853864A patent/US3646007A/en not_active Expired - Lifetime
- 1969-10-07 JP JP44079730A patent/JPS493999B1/ja active Pending
- 1969-12-11 CA CA069661A patent/CA920125A/en not_active Expired
- 1969-12-17 SE SE6917421A patent/SE384866B/xx unknown
- 1969-12-19 BR BR215483/69A patent/BR6915483D0/pt unknown
- 1969-12-30 DE DE1965431A patent/DE1965431C3/de not_active Expired
- 1969-12-30 DE DE1967073A patent/DE1967073C2/de not_active Expired
-
1970
- 1970-01-08 NO NO00067/70A patent/NO126800B/no unknown
- 1970-01-13 ES ES375387A patent/ES375387A1/es not_active Expired
- 1970-01-13 GB GB1252401D patent/GB1252401A/en not_active Expired
- 1970-01-15 NL NL707000574A patent/NL140735B/xx not_active IP Right Cessation
- 1970-01-23 CH CH97170A patent/CH530998A/de not_active IP Right Cessation
- 1970-08-18 DK DK422770AA patent/DK137801B/da not_active IP Right Cessation
- 1970-08-20 IL IL35135A patent/IL35135A/xx unknown
- 1970-08-20 PL PL1970142795A patent/PL80960B1/pl unknown
- 1970-08-25 YU YU2145/70A patent/YU36188B/xx unknown
- 1970-08-25 FR FR7030995A patent/FR2068522B1/fr not_active Expired
- 1970-08-26 AT AT776070A patent/AT299457B/de not_active IP Right Cessation
- 1970-08-26 PH PH11764*UA patent/PH9221A/en unknown
- 1970-08-28 LU LU61603D patent/LU61603A1/xx unknown
- 1970-08-28 SU SU1482906A patent/SU381216A3/ru active
- 1970-08-28 CS CS7000005929A patent/CS183616B2/cs unknown
- 1970-08-28 HU HUPA1074A patent/HU162297B/hu unknown
-
1971
- 1971-03-26 ZA ZA705913A patent/ZA705913B/xx unknown
- 1971-12-07 JP JP46098967A patent/JPS4921765B1/ja active Pending
-
1973
- 1973-05-28 PH PH14658*A patent/PH10011A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CH530998A (de) | 1972-11-30 |
| SU381216A3 (OSRAM) | 1973-05-15 |
| PH9221A (en) | 1975-07-10 |
| YU214570A (en) | 1981-04-30 |
| DE1965431C3 (de) | 1979-01-04 |
| NL140735B (nl) | 1974-01-15 |
| FR2068522A1 (OSRAM) | 1971-08-27 |
| DK137801C (OSRAM) | 1978-10-16 |
| DE1965431A1 (de) | 1971-04-08 |
| PL80960B1 (en) | 1975-08-30 |
| CS183616B2 (en) | 1978-07-31 |
| LU61603A1 (OSRAM) | 1971-08-05 |
| GB1252401A (OSRAM) | 1971-11-03 |
| BR6915483D0 (pt) | 1973-03-13 |
| ZA705913B (en) | 1971-04-28 |
| DE1965431B2 (de) | 1978-05-18 |
| AT299457B (de) | 1972-06-26 |
| SE384866B (sv) | 1976-05-24 |
| CA920125A (en) | 1973-01-30 |
| ES375387A1 (es) | 1972-05-01 |
| IL35135A0 (en) | 1970-10-30 |
| DE1967073A1 (de) | 1976-12-02 |
| DE1967073C2 (de) | 1986-04-17 |
| IL35135A (en) | 1974-07-31 |
| FR2068522B1 (OSRAM) | 1974-08-30 |
| HU162297B (OSRAM) | 1973-01-29 |
| BE755361A (fr) | 1971-03-01 |
| YU36188B (en) | 1982-02-25 |
| JPS4921765B1 (OSRAM) | 1974-06-04 |
| JPS493999B1 (OSRAM) | 1974-01-29 |
| PH10011A (en) | 1976-07-13 |
| DK137801B (da) | 1978-05-08 |
| NL7000574A (OSRAM) | 1971-03-02 |
| US3646007A (en) | 1972-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aoshima et al. | N 4-behenoyl-1-β-D-arabinofuranosylcytosine as a potential new antitumor agent | |
| NO126800B (OSRAM) | ||
| Ng et al. | L-Dopa-induced release of cerebral monoamines | |
| HUT67711A (en) | Tetrahydropyrimidine derivatives and pharmaceutical compositions comprising them | |
| JPH035398B2 (OSRAM) | ||
| IL28164A (en) | Substituted ammonium basic addition salts of ribonucleic acid and their preparation | |
| NO760752L (OSRAM) | ||
| Burton | Antibiotics from penicillia | |
| Gottschalk | The precursor of 2-carboxy-pyrrole in mucoproteins | |
| US4148888A (en) | 3-Deazaadenosine as an inhibitor of adenosylhomocysteine hydrolase with antiviral activity | |
| Parnas | The toxicity of Prymnesium parvum: A Review | |
| US3857940A (en) | Inosine derivatives | |
| US3728450A (en) | Inosine derivatives | |
| van Waarde et al. | Nitrogen metabolism in goldfish, Carassius auratus (L.). Influence of added substrates and enzyme inhibitors on ammonia production of isolated hepatocytes | |
| CN110564794A (zh) | 一种阿卡波糖的发酵方法 | |
| CN107619119B (zh) | 无磷缓蚀剂及其制备方法和应用以及水处理组合物及其应用 | |
| US4166847A (en) | Anti-nicotine agent prepared from a saccharide and rosin or turpentine | |
| Gates et al. | Effect of a cationic detergent on the digestion of raw cornstarch in vitro | |
| US20060105965A1 (en) | Method for enhancing energy levels and reducing the effects of stress using nutraceutical formulations | |
| TWI855282B (zh) | 水溶性幾丁聚醣高分子電解質複合物（ｐｅｃ）及其組合物與應用 | |
| D'Alessandro et al. | Does catalase play a role in adriamycin induced cardiotoxicity? | |
| Goetsch et al. | Glucocorticoid effects on respiration and metabolism by rat liver homogenates | |
| Dhar | Chemical Studies on Substituted Uracils in Relation to Tumour Growth | |
| SU1427781A1 (ru) | 4-Аминокарбонил- или 4-аминоэтил-5-метилпиразолы, обладающие способностью регулировать скорость выведени этанола | |
| JPS63316727A (ja) | 抗レトロウイルス剤 |